Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ovid Therapeutics Inc (OVID)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food...

OVID : 11.28 (-3.92%)
TKPYY : 27.1720 (+0.19%)
Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

- Phase 1 Clinical Trials of TAK-935/OV935 Demonstrated a Strong Safety Profile and Well Characterized Pharmacokinetic Profile, Supporting Further Clinical Advancement -

OVID : 11.28 (-3.92%)
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents

-- Results from the Phase 1 Clinical Trial of Adolescents with Angelman and Fragile X Syndromes Demonstrated OV101 was Well Tolerated with a Pharmacokinetic Profile Similar to Adults --

OVID : 11.28 (-3.92%)
Ovid Therapeutics to Participate in Two Upcoming Investor Conferences

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will participate in two upcoming...

OVID : 11.28 (-3.92%)
Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced financial results for the third quarter...

OVID : 11.28 (-3.92%)
Ovid Therapeutics to Participate at the Stifel 2017 Healthcare Conference

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Jeremy Levin, DPhil, MB BChir, chairman...

OVID : 11.28 (-3.92%)
Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced new positive preclinical data on OV101...

OVID : 11.28 (-3.92%)
Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome

Ovid Therapeutics, Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food...

OVID : 11.28 (-3.92%)
Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will provide a poster presentation...

OVID : 11.28 (-3.92%)
Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced the appointment of Ana C. Ward as senior...

OVID : 11.28 (-3.92%)
Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies

- Cornerstone of Robust Clinical Development Strategy

OVID : 11.28 (-3.92%)
Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced financial results for the second quarter...

OVID : 11.28 (-3.92%)
Ovid Therapeutics to be Added to Russell 2000(R), 3000(R) and Microcap(R) Indexes

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will be added to the Russell 2000,...

OVID : 11.28 (-3.92%)
Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced the appointment of Barbara G. Duncan to...

OVID : 11.28 (-3.92%)
Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress

Completed Initial Public Offering Raising $75 Million in Gross Proceeds

OVID : 11.28 (-3.92%)
Ovid Therapeutics Inc. (Nasdaq: OVID) to Ring The Nasdaq Stock Market Closing Bell

What:

NDAQ : 79.41 (+0.80%)
OVID : 11.28 (-3.92%)
Ovid Therapeutics Announces Pricing of Initial Public Offering

Ovid Therapeutics Inc., a biopharmaceutical company, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share,...

OVID : 11.28 (-3.92%)

Van Meerten Stock Picks

5 Great Large Caps
Today I wanted to find 5 Large Caps that still had some upside potential.
ALL -0.50 , AMP -0.85 , LB +0.23 , AXP +0.27 , AKAM +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.09%) this morning are up +0.08% and European stocks are down -0.12% . Most global stocks markets moved higher ahead of central bank meetings this week from the Fed, ECB and BOE. U.S.... Read More

Chart of the Day

Chart of the Day

Viking Therapeutics (VKTX) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter, a Weighted Alpha of 206.52+ and gained 254.95% in the last year
Read More

Brugler Ag Report

Today's Commentary

Corn futures are 1 to 2 cents lower this morning, with speculative attention drawn toward the beginning of bitcoin futures trading (+26% at one point overnight!). They saw gains of 1/4 to 1 1/4 cents on Friday, but nearby Dec was 1.38% for the week. ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.